Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes  by Hevey, Michael et al.
Characterization of monoclonal antibodies to Marburg virus (strain
Musoke) glycoprotein and identification of two protective epitopes
Michael Hevey,* Diane Negley, and Alan Schmaljohn
Virology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA
Received 28 October 2002; returned to author for revision 7 February 2003; accepted 25 April 2003
Abstract
Monoclonal antibodies (MAbs) reactive with Marburg virus (strain Musoke) were evaluated for both biological activity and specificity.
Several of the Marburg virus- (MBGV) specific MAbs reduced the size and/or number of MBGV plaques in vitro. The ability of the MAbs
to affect plaque formation in vitro was demonstrated to be specific for the glycoprotein (GP) of the strain of MBGV used for vaccination.
Using deletion analysis and peptide mapping, the binding epitopes of several of these neutralizing MAbs were identified. Not unexpectedly,
the epitopes were shown to lie in the most hypervariable and highly glycosylated region of MBGV GP. An analysis of the in vivo activity
of several MAbs revealed that some antibodies provided substantial but incomplete protection of naive guinea pigs by passive transfer.
These data suggest that neutralizing epitopes exist within MBGV GP but that induction of antibodies to these neutralizing epitopes may not
be sufficient for protection from lethal infection.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Marburg virus (MBGV), a member of the virus family
Filoviridae, is one of several causative agents of hemor-
rhagic fever characterized by high mortality rates (reviewed
in Slenczka, 1999; Peters and LeDuc, 1999). MBGV is
classified as an emerging pathogen, as it was first identified
in 1967 during an outbreak of hemorrhagic fever in Mar-
burg, Germany, and Belgrade, Yugoslavia, after the impor-
tation of infected monkeys from Uganda (Slenczka et al.,
1968; Wilson et al., 2001; Siegert et al., 1968). The char-
acteristic filamentous morphology of the virions was the
first indication that this virus was not related to animal
viruses known at that time. Then, in 1976, new outbreaks of
hemorrhagic fever were observed in both northern Zaire
(now the Democratic Republic of Congo) and southern
Sudan (Bowen et al., 1977; Johnson et al., 1977; Pattyn et
al., 1977). The virus isolated from victims of these two
outbreaks had the same filamentous morphology as MBGV
but was serologically distinct. This new virus, Ebola virus
(EBOV), was subsequently named after a river that flowed
near the village where the outbreak began. MBGV and
EBOV have since been characterized by both molecular and
classical serological techniques (Feldmann and Kiley,
1999). As a result, these two viruses were placed into
different genera of a new virus family, the Filoviridae. All
filoviruses possess a large negative sense, nonsegmented
RNA genome.
Although no licensed vaccines or treatments exist to
either MBGV or EBOV, we previously demonstrated that a
subunit vaccine, killed virus, or a recombinant vaccine
based on an alphavirus replicon protected guinea pigs from
MBGV virus challenge. A major protective antigen was
identified as the viral glycoprotein (GP) (Hevey et al., 1997,
2001). We later demonstrated that cynomolgus monkeys
vaccinated with MBGV GP, via an alphavirus replicon,
were completely protected from lethal MBGV challenge
(Hevey et al., 1998).
The protective antigen, MBGV GP, is a homotrimer
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embedded within a lipid membrane of the filamentous viral
particles (Feldmann et al., 1991). Because GP is the only
known viral protein on the surface of the virus membrane,
it remains possible that antibodies directed against this pro-
tein may possess neutralizing activity and/or be protective.
Furthermore, serum from animals that were inoculated with
inactivated MBGV and subsequently survived challenge
protected naive guinea pigs from lethal MBGV infection.
These data suggest that antibody of the right specificity to
MBGV GP may be useful as a postexposure treatment in
unvaccinated individuals (Hevey et al., 1997).
Characterization of a panel of currently existing mono-
clonal antibodies (MAbs) directed against MBGV (strain
Musoke) is described here. The identification of candidate
antibodies that have biological activity was achieved by
examining the MBGV MAbs for neutralizing activity in
vitro and subsequent passive protection in vivo. Several
MAbs demonstrated the ability to reduce either the number
and/or size of MBGV plaques on Vero E6 monolayers in a
strain specific manner. The epitopes that these “neutraliz-
ing” MBGV MAbs bound were identified and mapped to
residues in the central, most variable, region of MBGV GP
using both protein deletion analysis and peptide mapping.
Furthermore, these antibodies provided substantial protec-
tion when they were administered to guinea pigs prior to
MBGV challenge. The data presented here suggest that
anti-MBGV GP antibodies could potentially have therapeu-
tic value in reducing the mortality of MBGV disease.
Results
Assigning MAbs to competition groups
MAb groups were defined based on results from a com-
petition ELISAs. At least five distinct complementation
groups, made up of antibodies that were observed to inhibit
85–100% of the binding of a biotinylated MAb, were de-
fined from the MBGV GP-specific MAbs tested. Table 1
lists the complementation groups and the antibodies as-
signed to each group. Groups A, B, and C consisted of three
MAbs each. Groups D and E contained two MAbs and one
MAb, respectively.
Neutralization of MBGV by MAbs in vitro
The ability of MAbs to neutralize MBGV in vitro was
examined by plaque reduction assays. In the absence of
complement, most of the MAbs examined did not neutralize
virus. However, the MAbs in complementation groups A
and D reduced plaque size without affecting the plaque
number (Table 2). The ability to reduce the size of plaques
Table 1
Assigning MBGV GP-specific MAbs to specific complementation groups
Percent inhibition of binding of biotinylated MAbs in presence of excess unlabeled MAb
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was not strictly dependent on antibody concentration as
high dilutions of MAb still substantially reduced plaque
size. In contrast, when exogenous guinea pig complement
was included in the assay, MAbs in complementation
groups A and D were able to neutralize virus.
Passive immunization of guinea pigs with anti-MBGV
MAbs
Selected MAbs that were able to reduce the number
and/or size of plaques in an in vitro assay were evaluated
for protective efficacy in a guinea pig model. The con-
centration of MAb selected (3 mg/kg) was chosen from
previous dose-ranging studies; protection was demon-
strated to drop off below this concentration (Hevey et al.,
1997). Three MAbs representing three distinct comple-
mentation groups provided incomplete, but significant,
protection when administered prophylactically to guinea
pigs (Fig. 1). The most promising MAb was III 3H5,
which prevented death in more than 60% of the animals
and significantly extended the survival time in the re-
maining animals. In addition, two other MAbs, II 7G8
and III 3H10, were also partially protective and signifi-
cantly delayed time to death. Interestingly, using MAb III
3H5 and II 7G8 either in combination or sequentially
failed to improve the level of protection observed. This
suggests that the late deaths observed in animals treated
with these MAbs were not due to the selection of anti-
body escape variants during treatment. This was later
confirmed by demonstrating the reactivity of these two
Mabs with virus isolated from moribund guinea pigs by
indirect immunofluorescence assay (data not shown).
Table 2
Ability of MBGV GP-specific MAbs to affect the formation or size of
plaque development in vitro
Complementation
group
MAb 80% PRNTa Plaque size
reductionb
A III 3H5 25 
II 7E9 25 
II 7E10 25 
D III 7C11 25 
II 9F8 6.25 
NAc III 3H10 100 
NA II 7G8 100 
B III 5D7 100 
C II 9G4 100 
E III 4B11 100 
a In the presence of exogenous guinea pig complement and the indicated
concentration of MAb (g/ml), plaques were too small to count.
b In the absence of complement, the plaque number was unchanged;
however, plaque size was reduced to pinpoints in the presence of 25
g/ml MAb.
c Not assigned to a complementation group.
Fig. 1. Kaplan–Meier survival curves of naı¨ve guinea pigs administered the indicated monoclonal antibody (3 mg/kg) before challenge with Marburg virus
(Musoke). P values were calculated using a log rank test and comparing treatment groups to the control group which only received Hanks’ buffered saline
solution (HBSS).
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Mapping regions on MBGV GP that react with specific
MAbs
Carboxyterminal truncations were generated (Fig. 2A) as
described below in materials and methods, and the reactivity
of MAbs with the truncated peptides was analyzed. Figure
2B depicts the reactivity pattern of various MAbs with the
in vitro expressed, truncated MBGV gene using either a
western blot or radioimmunoprecipitation assay. The most
protective MAb, III 3H5, reacted with deletion products two
and three but not four in both Western blot and immuno-
precipitation assays, indicating the epitope for this MAb
resided between amino acids 270 and 369 in MBGV GP. In
addition, two other Mabs in the same complementation
Fig. 2. (A) Carboxyterminal deletion mutants of MBGV Musoke GP and the sequence of the PCR primers used to generate the deletions. Numbers in
parentheses indicate the C terminal amino acid of the deletion. (B) Reactivity of monoclonal antibodies with various in vitro expressed carboxyterminal
mutants of MBGV Musoke GP by either Western blot analysis or immunoprecipitation of 35S-labeled protein.
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group, II 7E9 and II 7E10, demonstrated the same reactivity
pattern. Two additional MAbs that were examined dis-
played different reactivity patterns. MAb III 5B8 did not
immunoprecipitate any of the deletion products, but did
react with products two and three, but not four, in Western
blot, indicating the possibility that the epitope for this MAb
was inaccessible, possibly due to improper folding, in non-
reducing conditions. MAb II 7C11 reacted only with dele-
tion product 2 in an immunoprecipitation assay, but reacted
with products 2 and 3 in Western blot.
Identification of protective epitopes in MBGV GP
The minimal epitopes to which the protective MAbs
bound were identified utilizing membranes onto which pep-
tides, corresponding to amino acids 193–509 of MBGV GP,
were synthesized. Figure 3 shows the reactivity of selected
MAbs with the peptides bound to a membrane. MAb III
3H5 reacted strongly with peptides 31 and 32. The sequence
of these overlapping peptides identified a minimal epitope
of nine amino acids corresponding to amino acids 317–325
on MBGV GP. MAbs II 7E9 (Fig. 3) and II 7E10 (not
shown) bound the same two peptides and also reacted with
peptide 29. The shared sequence between these peptides
was only five amino acids with identity to amino acids
317–321 on MBGV GP. The binding site of another pro-
tective MAb, II 7G8, was identified as amino acids 260–269
on MBGV GP.
The binding of MAbs to individual peptides was con-
firmed by evaluating the ability of excess synthetic peptide
in solution to inhibit the binding of individual MAbs to
MBGV antigen. Figure 4 shows the level of inhibition of
binding by 6 g of peptide, as well as the amount of peptide
required for inhibition of 50% binding.
Discussion
The characterization of MAbs specific for MBGV GP
resulted in the identification of several distinct antibodies
that had the potential for therapeutic use. Of the five
distinct complementation groups identified, antibodies in
two groups, A and D, were able to neutralize MBGV in
vitro in the presence of complement. Interestingly, in the
absence of complement the antibodies in these two
groups did not reduce the plaque number but did reduce
the plaque size. This may be due to the ability of these
Fig. 3. Identification of specific epitopes recognized by anti-MBGV mono-
clonal antibodies. Membranes probed with indicated antibody were as-
sayed for reactivity using a modified Western blot technique. Dark spots on
membrane indicate reactivity with the antibody.
Fig. 4. Inhibition of binding of biotinylated monoclonal antibodies by 6 g of peptide in an ELISA. The numbers above the bars indicate the concentration
of peptide required for 50% inhibition of binding.
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antibodies to prevent spread of virus rather than infection
of cells. Studies are currently underway to further define
the mechanism by which the antibodies in these two
groups inhibit virus growth in vitro.
In addition, the MAbs were evaluated for their ability
to protect naı¨ve guinea pigs from MBGV infection.
MAbs from three different complementation groups sig-
nificantly, but incompletely, protected guinea pigs when
they were administered prophylactically. Unexpectedly,
antibodies in complementation group D, which neutral-
ized virus in vitro, did not significantly protect in vivo.
However, antibodies in complementation group A, which
also neutralized virus in vitro, did significantly protect in
vivo. Furthermore, two additional antibodies, not as-
signed to any complementation groups, provided signif-
icant protection in vivo, but demonstrated no neutralizing
activity in vitro. These results suggest that the ability of
antibodies to neutralize MBGV in vitro does not correlate
with the ability of the antibody to protect in vivo. Thus,
when examining antibodies for potential as therapeutics
for MBGV infection, nonneutralizing antibodies should
not be overlooked.
The epitopes bound by several MAbs, which were
protective in vivo, were identified. Antibodies in comple-
mentation group A bound to an epitope corresponding to
amino acids 317–325. This epitope is located in a highly
variable region of MBGV GP and is found only in the
Musoke strain of MBGV. However, protective antibody
II 7G8 bound to amino acids 260 –269, which are con-
served between the two most divergent strains of MBGV,
Musoke and Ravn. This antibody does react with MBGV-
Ravn antigen in an ELISA, as is predicted from the
epitope mapping. MAb 7G8 was only one of two cross-
reactive MAbs obtained from the fusion, possibly indi-
cating that the immunodominant regions of GP are the
most variable regions. Current studies are underway to
generated more cross-reactive MAbs, with the goal of
identifying cross-protective antibodies. The ability of this
MAb to protect guinea pigs from MBGV Ravn infection
remains to be determined.
The data presented here indicate that antibodies di-
rected against MBGV GP may have a role in protection
from lethal infection. However, we have been unable to
identify any anti-GP antibodies that are completely pro-
tective. This may indicate that other immune responses,
specifically cell-mediated immune responses, are re-
quired to provide complete protection. Alternatively, the
MAbs obtained here represent a population that reflects
the method used to vaccinate the mice and likely do not
represent the same population of antibodies that would be
obtained by other methods of vaccination. To explore this
possibility further, we are currently generating additional
MAbs to MBGV GP elicited by vaccination with a viral
vector that expresses MBGV GP.
Materials and methods
Cell cultures and viruses
Vero E6 cells (Vero C1008, ATCC CRL 1586) were
grown in minimal essential medium with Earle’s salts sup-
plemented with 10% fetal bovine serum and gentamicin (50
g/ml). MBGV (strain Musoke) was isolated from a human
case in 1980 in Kenya (Smith et al., 1982). Because this
virus is virulent for nonhuman primates but not rodents, it
was adapted for guinea pig virulence as described previ-
ously (Hevey et al., 1997). MBGV (strain Ravn) was iso-
lated from a fatal human case in 1987 in Kenya (Johnson et
al., 1996). This virus was similarly adapted for guinea pig
lethality.
MBGV ELISA using purified MBGV as antigen
Antibody titers were determined by an indirect ELISA
as described previously (Hevey et al., 1997). Briefly,
antigen consisting of purified, irradiated virus was coated
directly onto PVC plates and serial dilutions of test an-
tibody were added to wells containing antigen. The pres-
ence of bound antibody was detected by use of the ap-
propriate horseradish peroxidase-conjugated antispecies
antibody (HPO-goat-antimouse GAM). Endpoint of reac-
tivity was defined as the dilution at which OD405 was 0.2
as determined by extrapolation of a four parameter curve
fit (SOFTmax, Molecular Devices Corp.) of background-
subtracted mean OD versus dilution. Results shown in
any table or figure are from a single assay to allow more
valid comparison of endpoints.
Biotinylation of MAbs and competition ELISA
Competition ELISA was performed as described for
ELISA with the following modifications. Fifty microliters
of excess MAb (1:50 dilution of neat ascitic fluid) was
incubated in antigen-coated wells in triplicate for 1 h at
room temperature. After 1 h, 50 l of a dilution of biotin-
labeled MAb empirically determined to yield an OD of
1.0 was added to the wells and incubated for an additional
hour at room temperature. The presence of bound antibody
was detected by use of streptavidin horseradish peroxidase.
The peptide competition was performed by mixing 100
ng of purified MAb with various dilutions of synthetic
peptide and incubating overnight at 4°C. Fifty microliters of
the peptide–MAb mixture was added to killed whole
MBGV antigen-coated wells and incubated for 1 h at room
temperature. After washing, the presence of bound antibody
was detected by use of the appropriate horseradish peroxi-
dase-conjugated antispecies antibody (HPO-goat-antimouse
GAM).
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MBGV infectivity assays
Plaque assays of serially diluted samples on Vero E6
cells with a semisolid overlay. Viral plaques were visualized
by staining viable cells with neutral red 6–7 days postin-
fection. To measure plaque reduction neutralization, equal
volumes of a viral stock (target plaque dose was 100
PFU) and antibodies diluted in cell culture medium, in
either the presence or the absence of 5% guinea pig com-
plement, were mixed and incubated at 37°C for 1 h. The
resulting sample was assayed by plaque assay on Vero E6
cells for more than a 50% reduction in PFU compared to
control samples.
Construction of deletion mutants of MBGV GP
A set of nested carboxyterminal deletions of MBGV GP
was generated using polymerase chain reaction (PCR) and
the MBGV GP gene cloned into pGem 3Zf() as a tem-
plate. Because the MBGV GP gene is in an orientation such
that it can be transcribed in vitro from the SP6 promoter, the
5 PCR primer was designed to anneal to the pGem vector
at the SP6 promoter. In addition, five 3 primers were
designed that resulted in a progressive truncation of the GP
gene. The sequence of the primers used is shown in Fig. 2A.
PCR was performed with 1 ng of pGem 3Zf()-MBGV GP,
1 g of each primer pair and PFU polymerase in a 100-l
reaction, according the manufacturer’s instructions. Cycling
was set for an initial denaturation step at 94°C for 3 min
followed by 30 cycles of 1 min at 94°C, 1 min at 55°C, and
1.5 min at 72°C, with a final extension step at 72°C for 5
min. Products were analyzed by agarose gel electrophoresis.
Expression of MBGV GP deletion mutants in vitro
In order to express the GP deletion mutants in vitro,
RNA was transcribed from the PCR fragment and protein
made in rabbit reticulocyte lysate. The PCR fragments were
cleaned up by phenol:chloroform extraction and ethanol
precipitation. Five microliters of each PCR reaction was
used for transcription of uncapped RNA using the Ribomax
(Promega, Madison WI) system according to manufactur-
er’s instructions. The resulting RNA was analyzed by elec-
trophoresis on an agarose gel. The RNA was heat denatured
at 65°C for 10 min and snap chilled on ice. Two microliters
of the RNA product was used in an in vitro translation
reaction using a rabbit reticulocyte lysate system according
to manufacturer’s instructions (Promega, Madison WI).
Western blot assay for MAb reactivity with MBGV GP
deletion mutants
Ten microliters of the in vitro translation mixture was
electrophoresed through a 12.5% sodium dodecyl sulfate
(SDS) polyacrylamide gel at 30 mA until the dye front
migrated 80% through the gel. The resulting proteins
were transferred to an immobilon-PVDF membrane using a
tank blotting system and Towbin buffer at 90 V for 1 h. The
membrane was incubated in PBS  0.05% Tween 20
(PBST) containing 5% nonfat dry milk overnight at 4°C.
After rinsing the membrane in PBST, it was incubated with
either undiluted cell culture supernatant harvested from the
appropriate hybridoma cell line or a 1:500 dilution of mouse
ascitic fluid (diluted in blocking solution) for 1 h at room
temperature. The membrane was washed three times in
PBST for 15, 5, and 5 min. The membrane was then incu-
bated with HPO-conjugated goat antimouse (1 mg/ml) IgG
 IgM  IgA (HL) diluted 1:1000 in blocking buffer for
1 h at room temperature. The membrane was washed three
times as previously described followed by a 1-min incuba-
tion in an HPO-specific chemiluminescent substrate (ECL,
Amersham Inc). The membrane was wrapped in clear plas-
tic and exposed to X-ray film for various times.
Use of SPOTS membrane for fine peptide mapping of
MBGV MAbs
SPOTS membranes were obtained from Genosys Inc.
(Woodlands, TX). The membranes consisted of 77 dif-
ferent spots onto which peptide 13-mers were attached.
The sequence of the peptides corresponded to amino
acids 193–507 of MBGV GP, and each peptide over-
lapped the preceding peptide by nine amino acids.
SPOTS membranes were rinsed in methanol once fol-
lowed by two rinses in PBST. As for the Western blot,
the membranes were blocked in PBST  5% milk over-
night at 4°C. Membranes were rinsed in PBST followed
by incubation with a 1:200 dilution of mouse ascitic fluid
(5 g/ml) in PBST  5% milk for 1.5 h at room
temperature. The membrane was washed, followed by
incubation with HPO-conjugated goat antimouse
IgGIgAIgM (HL) for 1.5 h at room temperature and
then further washing as described for the Western blot.
The SPOTS membrane was incubated 1 min in an HPO-
specific chemiluminescent substrate (ECL, Amersham
Inc). The membrane was wrapped in clear plastic and
exposed to X-ray film for various times.
Antibody on the SPOTS membrane was stripped off
using the following washing procedure: rinsed in 20 ml
milli-Q H2O for 10 min, repeated twice; washed in 20 ml
dimethylformamide for 10 min, repeated twice; washed in
20 ml milli-Q H2O for 10 min, repeated once; washed in 20
ml 8 M urea, 1% SDS, 0.1% 2-mercaptoethanol heated to
50°C, repeated twice; washed in 20 ml 50% ethanol, 10%
acetic acid, repeated twice; washed in 20 ml methanol,
repeated once. If the membrane was to be reused the next
day, it was then washed in 20 ml PBST for 10 min, repeated
twice, and blocked overnight in blocking solution. If the
membrane was to be stored, it was allowed to air dry and
was stored at 20°C in a desiccator.
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Passive transfer of ascitic fluids containing MBGV MAbs
Ascitic fluids containing MAbs to MBGV were inocu-
lated intraperitoneally (ip) into strain 13 guinea pigs before
infection (subcutaneous inoculation) with 1000 PFU guinea
pig-adapted MBGV. The amount of antibody administered
was 3 mg/kg and the volume of all inoculations of ascitic
fluid was normalized to 3 ml with sterile saline to account
for volume effects. If a second administration of antibody
was to be given, it was also given ip in a normalized volume
of 3 ml. Animals were examined daily for signs of illness.
Plasma was obtained from the retroorbital sinus of anesthe-
tized guinea pigs on day 7 postinfection.
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